ETASCAI Pilot Project

NCT06790849 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-11-19

No results posted yet for this study

Summary

This pilot study aims to investigate the chronic effects of ETAS® on cognitive, affective and inflammatory outcomes in healthy adults aged 60-80 years with mild to moderate subjective cognitive complaints.

Conditions

Cognition
Affect (Mental Function)
Inflammation

Interventions

DIETARY_SUPPLEMENT

Active 1 ETAS®

300 mg ETAS®

DIETARY_SUPPLEMENT

Active 2 ETAS®

1500mg ETAS®

DIETARY_SUPPLEMENT

Placebo

Matched placebo capsule

Sponsors & Collaborators

Amino Up Chemicals Co., Ltd.
collaborator INDUSTRY
University of Reading
lead OTHER

Study Design

Allocation: RANDOMIZED
Purpose: BASIC_SCIENCE
Masking: QUADRUPLE
Model: PARALLEL

Eligibility

Min Age: 60 Years
Max Age: 80 Years
Sex: ALL
Healthy Volunteers: Yes

Timeline & Regulatory

Start: 2025-02-24
Primary Completion: 2025-10-22
Completion: 2025-10-22

Countries

United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Inflammation

Summary

Conditions

Interventions

Sponsors & Collaborators

Study Design

Eligibility

Timeline & Regulatory

Countries

Study Locations

Related Clinical Trials

The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome

Effects of TA-65, a Telomerase Activator on Metabolic Syndrome

Nutritional Supplement's Effects on Cognition

Study of a Nutritional Supplement for Healthy Aging

Effect of TA-65MD on Healthy Volunteers

More Related Trials

Entities